Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achi...

Source: Journal of Hematology and Oncology - February 13, 2018 Category: Hematology Authors: Jian Li, Wenwen Li, Kejia Huang, Yang Zhang, Gary Kupfer and Qi Zhao Tags: Review Source Type: research